Schedule 13G ownership disclosure

Inhibikase Therapeutics Inc

Security class unavailable · CUSIP: 45719W205

Event date: 2024-10-09

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
Unavailable
Percent of class
9.9000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-24-109611
Form type
SC 13G
Filer
Fairmount Funds Management LLC
CIK
CIK 1802528
Filed
Oct 17, 2024
Reporting period
Oct 09, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub